• Add to address book
  • Printer friendly
  • Email this page to a friend
  • Generate a PDF version of this page

Michael M. Gaba

Partner
Washington, D.C.
t: 202-419-2435

Michael M. Gaba is a partner in the Washington, D.C. office of Holland & Knight where he is the federal policy leader of the firm’s national Healthcare & Life Sciences Team. His regulatory and legislative life sciences practice includes counseling and representing medical device and biotech companies before the Food and Drug Administration, the Centers for Medicare and Medicaid Services, and the U.S. Congress. More specifically, Mr. Gaba works on a range of issues related to healthcare reform, with an emphasis on HHS integration, the FDA Amendments Act, post-market surveillance and enforcement, with a particular focus on combination product approval and labeling, as well as coverage, coding, and reimbursement for these sophisticated products.

Mr. Gaba also represents national not-for-profit organizations before the legislative branch and the National Institutes of Health on healthcare policy and funding matters.

Mr. Gaba writes extensively and lectures on a range of healthcare issues, including comparative effectiveness, interagency coordination and its impact in the post-market context, defending FDA enforcement actions, as well as on coverage, coding, and reimbursement strategies for medical device manufacturers.

Mr. Gaba worked on Capitol Hill in the personal offices of Congressman Robert Garcia (D-NY) and Senator Bill Bradley (D-NJ), and on the Labor and Human Resources Committee for Senator Edward Kennedy (D-MA).

Professional Honors & Awards

  • Chambers USA – America's Leading Business Lawyers guide, Healthcare: Pharmaceutical/Medical Products Regulatory, 2007-2011
  • Food & Drug Law Institute, Food & Drug Law Journal Editorial Advisory Board, 2009-present
  • Bloomberg BNA Medical Devices Law & Industry Report - Advisory Board, 2007-present
  • Food & Drug Law Institute, H. Thomas Austern Writing Awards Committee, 2006-2010

Memberships

  • American Health Lawyers Association
  • Maryland Bar Association
  • District of Columbia Bar Association

Speaking Engagements

  • "Interagency Coordination Regarding Medical Products: The Effect on Coverage, Payment, Fraud and Abuse," The Food and Drug Law Institute Conference, September 12, 2011
  • "Developing a Regulatory Approval Strategy that Will Satisfy Manufacturers’ Coverage and Reimbursement Objectives," Medical Device Pricing & Reimbursement, American Conference Institute, June 13, 2011
  • "CMS, FDA and the 'Parallel Review Process,'" Bureau of National Affairs "Thought Leadership" Video Series, April 2011
  • "CMS-FDA MOU and Parallel Review: Understanding the Impact of CMS-FDA Data Sharing Agreement on Market Access and Reimbursement," Annual Pharmaceutical Reimbursement & Market Access Conference, December 7, 2010
  • "CMS-FDA MOU Spells Opportunities and Challenges for the Life Sciences Industry," Center for Business Intelligence Webinar, October 6, 2010
  • "The Next Steps of Comparative Effectiveness," Medical Device Manufacturers Association Annual Coverage, Reimbursement and Health Policy Conference, Washington, D.C., November 10, 2009
  • "Coverage, Coding and Payment-Collaboration Between FDA and CMS," Food and Drug Law Institute - Introduction to Medical Device Law and Regulation: A Program on Understanding How the Government Regulates the Medical Device Industry, July 31, 2009
  • "Comparative Effectiveness and Healthcare Policy Update," LifeScience Alley Program, March 17, 2009
  • "Overview of Medical Device Law and Regulation," FDLI Workshop on Introduction to Medical Device Law and Regulation, February 26, 2009
  • "Interagency Collaboration: Risk Assessment by FDA & CMS, A Glimpse at our Future," Food and Drug Law Institute Conference: Better Understanding CMS and Its Relationship to FDA, The Regulation of and Payments for Drugs and Medical Devices, November 18, 2008
  • "Comparative Effectiveness: Preparing for What's Next," Medical Device Manufacturers Association Conference: 11th Annual Coverage, Reimbursement and Health Policy Conference, November 12, 2008
  • "How to Respond to a 483 and Warning Letter," AdvaMed Conference: Integrating Your Complaint Handling System with CAPA and Management Review, January 18, 2007
  • Moderator, "Implementing Coverage with Evidence Development," Medical Device Manufacturers Association Ninth Annual Coverage and Reimbursement Conference, Washington, D.C., November 9, 2006
  • "Overview of Medical Device Law and Regulation," Food and Drug Law Institute's Workshop on Introduction to Medical Device Law and Regulation, November 8, 2006
  • Co-Chairman, Food and Drug Law Institute's Conference on The Implications for Industry of a Coordinated FDA and CMS - A Blurring of Regulatory Authority?, December 5, 2005

Published Articles & Books